Full Product Details
Author: John H. Scholefield (University Hospital, Nottingham, UK) ,
Herand Abcarian (University of Illinois College of Medicine) ,
Tim Maughan (University of Cardiff, Cardiff, UK) ,
Axel Grothey (Mayo Clinic, Rochester, MN, USA)
Publisher: John Wiley and Sons Ltd
Imprint: Wiley-Blackwell
Edition: 2nd edition
Dimensions:
Width: 16.30cm
, Height: 2.20cm
, Length: 24.00cm
Weight: 0.703kg
ISBN: 9781405127066
ISBN 10: 1405127066
Pages: 296
Publication Date: 14 June 2006
Audience:
Professional and scholarly
,
Professional & Vocational
Format: Hardback
Publisher's Status: Active
Availability: Out of stock
The supplier is temporarily out of stock of this item. It will be ordered for you on backorder and shipped when it becomes available.
Reviews
The text is extremely well references and well illustrated and provides a worthwhile edition to the library of all workers in the field. Colorectal Disease, 2007 A good book looking at the total management of patients with this condition and aimed at the entire medical team caring fro those with colorectal cancer. Digestive and Liver Disease, 2007 From a review of the first edition: More knowledge of molecular biology, better definition of risk groups, better screening, further development of risk- oriented combination therapy, and more meticulous surgery may yield much higher cure rates for colon and rectal cancer. Scholefield's book is one of the best starting points for a journey through the world of established, new, and evolving treatments for these diseases. New England Journal of Medicine, September 2000
The text is extremely well references and well illustrated and provides a worthwhile edition to the library of all workers in the field. Colorectal Disease, 2007 A good book looking at the total management of patients with this condition and aimed at the entire medical team caring fro those with colorectal cancer. Digestive and Liver Disease, 2007 From a review of the first edition: More knowledge of molecular biology, better definition of risk groups, better screening, further development of risk- oriented combination therapy, and more meticulous surgery may yield much higher cure rates for colon and rectal cancer. Scholefield's book is one of the best starting points for a journey through the world of established, new, and evolving treatments for these diseases. New England Journal of Medicine, September 2000 Robert W Beart, Jr., states in the foreword that this book provides an up-to-date record of the rapidly evolving alternatives in chapters which span the gamut from prevention through palliation. It is written for subspecialist physicians, nurses, and other members of the medical team. The emphasis throughout is providing this team with concrete, useful information. Although the authors are predominantly from the U.K., European and American issues are identified throughout. (Carol Scott-Conner, MD, PhD, MBA, @Doody's Review Service)
Author Information
Professor John Scholefield is Professor of surgery at University Hospital in Nottingham. He is doing research into possible screening tests for spotting colorectal cancer early and cell changes in colorectal cancer. He chairs the National Cancer Research Institute's colorectal cancer group, and is also a member of Council of the Association of Surgeons. Professor Herand Abcarian MD FACS, Turi Josefsen Professor and Chairman of the Department of Surgery, University of Illinois College of Medicine at Chicago, USA. Professor Tim Maughan, Professor of Cancer Studies at the University of Wales, College of Medicine, and Consultant Clinical Oncologist at the Velindre Hospital Swansea. Also Chairman of the All Wales Cancer Network. Professor Axel Grothey, Mayo Clinic, USA (formerly Professor of Medicine and Oncology at Martin Luther University, Halle, Germany).
